PDF(Pubmed)
Abstract：
BACKGROUND: Allergic rhinitis (AR) is increasingly prevalent in India, affecting a significant portion of the population and adversely impacting their quality of life. This nationwide survey aimed to explore the perceptions and clinical preferences of Indian physicians regarding the perceived prevalence, common symptoms, and various available treatments for AR.
METHODS: This cross-sectional, observational, digital questionnaire-based survey was conducted from September 2022 to March 2023, involving physicians sharing insights on prevalence rates, diagnostic approaches, medication preferences, and immunotherapy practices in AR management.
RESULTS: A total of 1608 physicians participated in this survey. The majority of physicians (n=684, 42.5%) reported that the prevalence of AR in routine clinical practice is between 21 and 40%. Physicians also noted a substantial burden of AR with asthma (n=626, around 40%). Total IgE count was reported as a mandatory test for the diagnosis of AR by 47.5% of physicians (n=764). For the management of mild cases of seasonal or perennial AR, 980 (60.9%) physicians preferred fexofenadine as an oral antihistamine of choice. Fluticasone furoate was the preferred intranasal corticosteroid (INCS) option (67.1% of physicians (n=1079)), for the management of patients with moderate to severe AR, the most recommended duration of INCS therapy was two to four months (40.9% of physicians). Doctors recommended a montelukast and antihistamine combination in mild AR (n=152, 9.5%), mild AR not responding to antihistamine alone (n=291, 18.1%), moderate to severe AR along with INCS (n=252, 15.7%), and AR with mild asthma (n=74, 4.6%). The majority of physicians (n=1512, 75.6%) preferred using fexofenadine in combination with montelukast for the management of AR. The majority of physicians (n=839, 52.2%) opined that the efficacy rate of oral montelukast-fexofenadine was 60-90% in the management of mild-moderate AR. Around 55.3% of physicians (n=889) had not used immunotherapy in their clinical practice.
CONCLUSIONS: These observations offer a holistic view of how Indian physicians perceive the management of AR, a condition highly prevalent in India and often associated with asthma. It also highlights the treatment strategies employed in their day-to-day clinical practice.
METHODS: This cross-sectional, observational, digital questionnaire-based survey was conducted from September 2022 to March 2023, involving physicians sharing insights on prevalence rates, diagnostic approaches, medication preferences, and immunotherapy practices in AR management.
RESULTS: A total of 1608 physicians participated in this survey. The majority of physicians (n=684, 42.5%) reported that the prevalence of AR in routine clinical practice is between 21 and 40%. Physicians also noted a substantial burden of AR with asthma (n=626, around 40%). Total IgE count was reported as a mandatory test for the diagnosis of AR by 47.5% of physicians (n=764). For the management of mild cases of seasonal or perennial AR, 980 (60.9%) physicians preferred fexofenadine as an oral antihistamine of choice. Fluticasone furoate was the preferred intranasal corticosteroid (INCS) option (67.1% of physicians (n=1079)), for the management of patients with moderate to severe AR, the most recommended duration of INCS therapy was two to four months (40.9% of physicians). Doctors recommended a montelukast and antihistamine combination in mild AR (n=152, 9.5%), mild AR not responding to antihistamine alone (n=291, 18.1%), moderate to severe AR along with INCS (n=252, 15.7%), and AR with mild asthma (n=74, 4.6%). The majority of physicians (n=1512, 75.6%) preferred using fexofenadine in combination with montelukast for the management of AR. The majority of physicians (n=839, 52.2%) opined that the efficacy rate of oral montelukast-fexofenadine was 60-90% in the management of mild-moderate AR. Around 55.3% of physicians (n=889) had not used immunotherapy in their clinical practice.
CONCLUSIONS: These observations offer a holistic view of how Indian physicians perceive the management of AR, a condition highly prevalent in India and often associated with asthma. It also highlights the treatment strategies employed in their day-to-day clinical practice.
摘要：
背景：变应性鼻炎（AR）在印度越来越普遍，影响了很大一部分人口，并对他们的生活质量产生了不利影响。这项全国性的调查旨在探讨印度医生对感知患病率的看法和临床偏好，常见症状,和AR的各种可用治疗方法。
方法：这个横截面，观察,2022年9月至2023年3月进行了基于数字问卷的调查，医生分享了对患病率的见解，诊断方法，药物偏好，和AR管理中的免疫治疗实践。
结果：共有1608名医生参与了这项调查。大多数医生（n=684，42.5％）报告说，在常规临床实践中AR的患病率在21％至40％之间。医生还注意到哮喘患者的AR负担很大（n=626，约40％）。47.5％的医生（n=764）将总IgE计数报告为诊断AR的强制性测试。对于季节性或多年性AR的轻度病例的管理，980名（60.9％）医生首选非索非那定作为口服抗组胺药。糠酸氟替卡松是首选的鼻内皮质类固醇（INCS）选择（67.1％的医生（n=1079）），对于中度至重度AR患者的管理，最推荐的INCS治疗持续时间为2~4个月(40.9%的医师).医生建议在轻度AR中使用孟鲁司特和抗组胺药（n=152，9.5％），轻度AR对单独抗组胺药无反应（n=291，18.1%），中度至重度AR以及INCS（n=252，15.7%），和AR伴轻度哮喘（n=74，4.6％）。大多数医生（n=1512，75.6％）更喜欢使用非索非那定与孟鲁司特联合治疗AR。大多数医生（n=839，52.2％）认为口服孟鲁司特-非索非那定在轻度-中度AR治疗中的有效率为60-90％。大约55.3%的医生(n=889)在临床实践中没有使用过免疫治疗。
结论：这些观察提供了印度医生如何看待AR管理的整体观点，一种在印度非常普遍的疾病，通常与哮喘有关。它还强调了日常临床实践中采用的治疗策略。
方法：这个横截面，观察,2022年9月至2023年3月进行了基于数字问卷的调查，医生分享了对患病率的见解，诊断方法，药物偏好，和AR管理中的免疫治疗实践。
结果：共有1608名医生参与了这项调查。大多数医生（n=684，42.5％）报告说，在常规临床实践中AR的患病率在21％至40％之间。医生还注意到哮喘患者的AR负担很大（n=626，约40％）。47.5％的医生（n=764）将总IgE计数报告为诊断AR的强制性测试。对于季节性或多年性AR的轻度病例的管理，980名（60.9％）医生首选非索非那定作为口服抗组胺药。糠酸氟替卡松是首选的鼻内皮质类固醇（INCS）选择（67.1％的医生（n=1079）），对于中度至重度AR患者的管理，最推荐的INCS治疗持续时间为2~4个月(40.9%的医师).医生建议在轻度AR中使用孟鲁司特和抗组胺药（n=152，9.5％），轻度AR对单独抗组胺药无反应（n=291，18.1%），中度至重度AR以及INCS（n=252，15.7%），和AR伴轻度哮喘（n=74，4.6％）。大多数医生（n=1512，75.6％）更喜欢使用非索非那定与孟鲁司特联合治疗AR。大多数医生（n=839，52.2％）认为口服孟鲁司特-非索非那定在轻度-中度AR治疗中的有效率为60-90％。大约55.3%的医生(n=889)在临床实践中没有使用过免疫治疗。
结论：这些观察提供了印度医生如何看待AR管理的整体观点，一种在印度非常普遍的疾病，通常与哮喘有关。它还强调了日常临床实践中采用的治疗策略。
